Multiple Myeloma
News
FDA approves belantamab in relapsed/refractory multiple myeloma
The first-in-class drug belantamab mafodotin (Blenrep) has been approved in the United States for use in relapsed and refractory multiple myeloma...
Latest News
E.U. gives thumbs up for belantamab in R/R multiple myeloma
From the Journals
MM patients with concurrent AL show poor survival when coupled to cardiac dysfunction
Cardiac dysfunction is a major determinant of poor survival in multiple myeloma patients with concurrent light chain amyloidosis.
From the Journals
Transitioning regimen may prolong proteasome inhibitor–based therapy for MM
Transitioning from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone increased PI-based treatment adherence/...
Conference Coverage
Isa-Kd improves PFS in relapsed/refractory multiple myeloma
Conference Coverage
Tandem transplantation, long-term maintenance may extend MM remission
From the Journals
Vaccination regimen effective in preventing pneumonia in MM patients
From the Journals
Transplant beats bortezomib-based therapy for MM, but questions remain
From the Journals
Combo therapy with melflufen promising in small r/r multiple myeloma study
Feature
ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
From the Journals
Frailty indexes fail in sorting elderly MM patients
Three different indexes had surprisingly little overlap in identifying frailty among older multiple myeloma patients.